Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahito Atsuta

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The Prostate|June 29, 2022
Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancerTakafumi Yanagisawa, Takahiro Kimura, Kenichi Hata, et al.
Clinical Genitourinary Cancer|April 4, 2026
Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With DenosumabYuzo Inaba, Fumihiko Urabe, Yu Imai, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 16, 2025
Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative StudyFumihiko Urabe, Kojiro Tashiro, Yu Imai, et al.
Prostate International|April 11, 2025
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, et al.
Japanese Journal of Clinical Oncology|April 8, 2025
Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective studyFumihiko Urabe, Yuki Taneda, Naoki Uchida, et al.
Clinical Genitourinary Cancer|May 10, 2025
Optimal Cystoscopic Surveillance Schedule Following Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaYuhei Koike, Fumihiko Urabe, Katsuki Muramoto, et al.
Japanese Journal of Clinical Oncology|January 25, 2026
Tumor cell invasion of blood vessels predicts poor survival in upper tract urothelial carcinoma following radical nephroureterectomyMiyaka Umemori, Shun Sato, Fumihiko Urabe, et al.
Urologic Oncology|March 1, 2025
Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter studyFumihiko Urabe, Kojiro Tashiro, Katsuki Muramoto, et al.
Japanese Journal of Clinical Oncology|January 17, 2025
Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative studyYuki Taneda, Fumihiko Urabe, Naoki Uchida, et al.
Urologic Oncology|May 19, 2026
Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPCShuhei Hara, Keiichiro Mori, Ryotaro Yamaguchi, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The Prostate|June 29, 2022
Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancerTakafumi Yanagisawa, Takahiro Kimura, Kenichi Hata, et al.
Clinical Genitourinary Cancer|April 4, 2026
Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With DenosumabYuzo Inaba, Fumihiko Urabe, Yu Imai, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 16, 2025
Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative StudyFumihiko Urabe, Kojiro Tashiro, Yu Imai, et al.
Prostate International|April 11, 2025
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, et al.
Japanese Journal of Clinical Oncology|April 8, 2025
Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective studyFumihiko Urabe, Yuki Taneda, Naoki Uchida, et al.
Clinical Genitourinary Cancer|May 10, 2025
Optimal Cystoscopic Surveillance Schedule Following Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaYuhei Koike, Fumihiko Urabe, Katsuki Muramoto, et al.
Japanese Journal of Clinical Oncology|January 25, 2026
Tumor cell invasion of blood vessels predicts poor survival in upper tract urothelial carcinoma following radical nephroureterectomyMiyaka Umemori, Shun Sato, Fumihiko Urabe, et al.
Urologic Oncology|March 1, 2025
Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter studyFumihiko Urabe, Kojiro Tashiro, Katsuki Muramoto, et al.
Japanese Journal of Clinical Oncology|January 17, 2025
Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative studyYuki Taneda, Fumihiko Urabe, Naoki Uchida, et al.
Urologic Oncology|May 19, 2026
Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPCShuhei Hara, Keiichiro Mori, Ryotaro Yamaguchi, et al.
Pageof 3